NL-OMON34213
Completed
Phase 2
Botulinum toxin as a new treatment modality for jerky psychogenic movement disorders: a monocenter randomized controlled trial - Botulinum neurotoxin as treatment in psychogenic jerks
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- conversion disorder
- Sponsor
- Academisch Medisch Centrum
- Enrollment
- 50
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Eligible patients for the study have at least one consistent type of jerk of psychogenic origin. Two movement disorder specialists have to agree on the diagnosis based on clinical characteristics and on additional investigations if considered necessary. The diagnosis of psychogenic jerks needs to have a \*definite\* or \*probable\* level of certainty for psychogenic movement disorders. The jerk of interest has to significantly disable the patient in his/her daily functioning according to the patient and the movement disorder specialists and needs to be performed by a muscle or muscles amendable to injection. The jerk of interest may be simple or complex if only treatment with BoNT is considered possible.
Exclusion Criteria
- •\* Age \< 18 years or \> 80 years;
- •\* Psychogenic jerk of interest present for \< 1 year;
- •\* Previous or current treatment with BoNT;
- •\* Legally incompetent adult;
- •\* Pregnancy;
- •\* Coagulation disorders;
- •\* Insufficient knowledge of Dutch language
- •\* No informed consent
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
The efficacy of botulinum toxin in the treatment of chronic neck symptoms after whiplash injuriesMusculoskeletal Diseases: Neck painMusculoskeletal DiseasesNeck painISRCTN36437589Record Provided by the NHSTCT Register - 2004 Update - Department of Health (UK)100
Not yet recruiting
Not Applicable
Botuline toxine als nieuwe behandeling voor onverklaarde schokken.psychogenic movement disorderNL-OMON28532Academic Medical CentreMeibergdreef 91105 AZ Amsterdam54
Recruiting
Phase 4
Efficacy of botulinum toxin A for the management of melasma: A split-face, randomized control studyClinical diagnosis of melasma with symmetrical involvement of both malar areasMelasmaTCTR20240721002Division of Dermatology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand30
Not yet recruiting
Not Applicable
The combination treatment of Botulinum toxin and ablative fractional CO2 lasering to prevent scar formation after thyroidectomy and removal of neck massKCT0006396The Catholic University of Korea, St. Vincent's Hospital75
Completed
Not Applicable
se of Botulinum Toxin for Treatment of Idiopathic Rhinitisidiopathic rhinitisC08.460.799RBR-4jbw4sFaculdade de Medicina da Universidade de São Paulo